Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.35
+0.24 (0.85%)
Mar 24, 2026, 4:00 PM EDT - Market closed
Agios Pharmaceuticals Employees
As of December 31, 2025, Agios Pharmaceuticals had 540 total employees, including 539 full-time and 1 part-time employees. The number of employees increased by 52 or 10.66% compared to the previous year.
Employees
540
Change (1Y)
52
Growth (1Y)
10.66%
Revenue / Employee
$100,052
Profits / Employee
-$764,409
Market Cap
1.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 540 | 52 | 10.66% | 539 | 1 |
| Dec 31, 2024 | 488 | 102 | 26.42% | 486 | 2 |
| Dec 31, 2023 | 386 | -7 | -1.78% | 383 | 3 |
| Dec 31, 2022 | 393 | 1 | 0.26% | 389 | 4 |
| Dec 31, 2021 | 392 | -170 | -30.25% | 390 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Recursion Pharmaceuticals | 600 |
| Vericel | 398 |
| Harmony Biosciences Holdings | 293 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| Soleno Therapeutics | 182 |
| Innoviva | 159 |
AGIO News
- 22 days ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - GlobeNewsWire
- 5 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - GlobeNewsWire
- 2 months ago - Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - GlobeNewsWire
- 3 months ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript - Seeking Alpha